<?xml version="1.0" encoding="UTF-8"?>
<p>The RDI of IRI tended to be lower compared with OX in aCRCS A1 + B1, but there was no difference in aCRCS A2 and B2 (Figure 
 <xref rid="cas14841-sup-0001" ref-type="supplementary-material">S4A</xref>). The RDI of fluoropyrimidines (5‐fluorouracil [5‐FU] or capecitabine) in the OX group was significantly lower than the RDI of S‐1 in the IRI group in aCRCS A2, but there was no difference in aCRCS A1 + B1 and B2 (Figure 
 <xref rid="cas14841-sup-0001" ref-type="supplementary-material">S4B</xref>). In addition, there was no difference in the RDI of bevacizumab between OX and IRI groups in all aCRCS (Figure 
 <xref rid="cas14841-sup-0001" ref-type="supplementary-material">S4C</xref>).
</p>
